SPRB vs TVTX
SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B. TVTX: Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first disease-modifying treatment for homocystinuria.
Side-by-side fundamentals
| Metric | SPRB | TVTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $41.99 | $56.68 | |
| Market cap as of 2026-08-01 | $116M | $5.3B | |
| PEG as of 2026-08-01 | n/a | 1.04 | |
| Net margin as of 2026-08-01 | -1079.9% | -4.0% | TVTX higher |
| Gross margin as of 2026-08-01 | n/a | +98.6% | |
| Operating margin as of 2026-08-01 | -1143.4% | -10.6% | TVTX higher |
| ROE as of 2026-08-01 | -155.4% | -26.8% | TVTX higher |
| ROA as of 2026-08-01 | -101.7% | -3.8% | TVTX higher |
| Debt / equity as of 2026-08-01 | 0.19 | 3.16 | SPRB lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +96.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +64.9% | |
| Beta as of 2026-08-01 | 3.47 | 1.02 | |
| 1-year return as of 2026-07-27 close | n/a | +270.0% |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.